About CARVYKTI®
How CARVYKTI® works
Manufacturing CARVYKTI®
CARVYKTI® Efficacy
CARTITUDE-4
Primary Analysis
Study Design
Progression-Free Survival (PFS)
Overall Survival (OS)
Depth of Response
Duration of Response
Time to Next Treatment (TTNT)
CARTITUDE-4
Follow-Up Analysis
Progression-Free Survival (PFS)
Overall Survival (OS)
Depth of Response
Duration of Response
CARTITUDE-1
Primary Analysis
Study Design
Depth of Response
Duration of Response
Time To Response
CARTITUDE-1
5-year Follow-Up Analysis
5-Year Baseline Characteristics
5-Year Duration Of Response
CARVYKTI® Safety
Boxed Warning
Cytokine Release
Syndrome (CRS)
Neurologic Toxicities
Hemophagocytic
Lymphohistiocytosis (HLH)
Prolonged and/or
Recurrent Cytopenias
Immune Effector Cell-Associated Enterocolitis
Secondary Malignancies
Additional Warnings & Precautions, and ARs ≥10%
Long-Term Safety
Treatment Process
Patient Identification
Steps in the Treatment Process
Resources
For Physicians
For Nurses/APPs
For Patients/Care Partners
Patient Support Program
For Access and Reimbursement Support
For Order Management
Urgency to Treat Earlier
Attrition Rates
T-cell Fitness and
Bridging Therapy
Treatment Centers
Coverage Lookup
Get In Touch
CARVYKTI® Prescribing Information
Contact Us
Go To Patient Website
Prescribing Information
CARVYKTI® PRESCRIBING INFORMATION
CARVYKTI® LA INFORMACIÓN DE PRESCRIPCIÓN
Get In Touch
Contact Us
For US Healthcare Professionals
Go To Patient Website
Treatment Centers
Coverage Lookup